Start of ‘Warring States’ in hepatitis C market
The hepatitis C treatment market has met the ‘Warring States’ period.
The Ministry of Food and Drug Safety(MFDS) has approved ‘Mavyret,’ an AbbVie Korea’s hepatitis C therapy, on 12 January.
‘Mavyret’ was approved as a hepatitis C therapy type 1 to 6 from the U.S. FDA on 3 August 2017, and is a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
